We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Longeveron Inc | NASDAQ:LGVN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.03 | -1.79% | 1.65 | 1.65 | 1.66 | 1.71 | 1.65 | 1.67 | 133,439 | 19:34:42 |
A live webcast of the presentation will be available via the Investors & Media section of the Company website. Following the live webcast, an archived replay of the webcast will be available on the website.
Longeveron management will be conducting 1x1 meetings during the conference. To schedule a meeting, please visit Dawson James Small Cap Growth Conference.
Dawson James’ flagship Small Cap Growth Conference will bring together senior executives from approximately 40 small-cap growth companies operating at the forefront of the healthcare, technology and consumer sectors. The conference brings together institutional funds, family offices and high-net-worth accredited investors. For more information on the conference and how to register, please visit https://dawsonjames.com/.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Additional information about the Company is available at www.longeveron.com.
Investor Contact:
Brendan PayneStern Investor RelationsOffice Direct: 212-698-8695 |Office Main: 212-362-1200brendan.payne@sternir.com | www.sternir.com
Source: Longeveron IncSource: LGVN
1 Year Longeveron Chart |
1 Month Longeveron Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions